Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study
| Autor: | Fernando Góngora-Rivera, Camilo Ríos, Paloma Calzada, Juan Nader-Kawachi, José Santos-Zambrano |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Time Factors Pilot Projects Dapsone Placebo Severity of Illness Index law.invention Brain ischemia Randomized controlled trial Double-Blind Method Modified Rankin Scale law Severity of illness medicine Humans cardiovascular diseases Aged Retrospective Studies Aged 80 and over Dose-Response Relationship Drug Cerebral infarction business.industry General Medicine Middle Aged medicine.disease Clinical trial Stroke Neuroprotective Agents Treatment Outcome Neurology Ischemic Attack Transient Anesthesia Female Neurology (clinical) business medicine.drug Follow-Up Studies |
| Zdroj: | Neurological research. 29(3) |
| ISSN: | 0161-6412 |
| Popis: | In a previous study of brain ischemia in rats, dapsone (4,4'-diamino-diphenylsulfone) was associated with a neuroprotective effect. As dapsone is safe and relatively free of adverse reactions, we conducted a pilot clinical trial to assess the possibility of using this drug in patients with a cerebral infarction.A double-blind, placebo-controlled, pilot clinical trial of dapsone was conducted from January 1999 to January 2000. Thirty patients with a CT or MRI documented ischemic stroke in the territory of the middle cerebral artery were included. Patients with4 points of the National Institute of Health Stroke Scale (NIHSS) were randomly allocated to receive either a single dose of 200 mg dapsone or placebo. For follow-up, NIHSS on days 0, 2, 7 and 60, modified Rankin scale and Barthel index at day 60 were applied. Adverse reactions were also recorded. The main cut point was considered when a patient obtained a variation of 2 points for modified Rankin scale and 17 points for Barthel index.Fifteen patients received dapsone and 15 received placebo. Twenty-nine were followed up for 60 days and one patient in the treatment group died during follow-up. Favorable scores were achieved for treated patients by all different measures; NIHSS (p=0.032), Barthel (p=0.049) and Rankin scale (RR=0.182, 95% CI: 0.04 and 0.86). Best results were obtained when treatment started within the first 8-10 hours after stroke. No adverse reactions related to medication were reported.Dapsone appears as a useful and safe drug for the treatment of stroke patients. Results of this pilot trial are promising and support further research to define the role of dapsone as a neuroprotective drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|